-
Mashup Score: 7Announcement of top-line results - TUDCA ALS - 1 month(s) ago
The TUDCA-ALS consortium announces top-line results from the European phase 3 clinical trial of TUDCA in patients with amyotrophic lateral sclerosis (ALS). 2024-03-27 Summary of outcomes: The TUDCA-ALS study did not meet the primary endpoint, measured by ALSFRS-R scores (a measure of functional and motor changes in ALS). There were also no significant differences observed […]
Source: www.tudca.euCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 7Announcement of top-line results - TUDCA ALS - 1 month(s) ago
The TUDCA-ALS consortium announces top-line results from the European phase 3 clinical trial of TUDCA in patients with amyotrophic lateral sclerosis (ALS). 2024-03-27 Summary of outcomes: The TUDCA-ALS study did not meet the primary endpoint, measured by ALSFRS-R scores (a measure of functional and motor changes in ALS). There were also no significant differences observed […]
Source: www.tudca.euCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 7Announcement of top-line results - TUDCA ALS - 1 month(s) ago
The TUDCA-ALS consortium announces top-line results from the European phase 3 clinical trial of TUDCA in patients with amyotrophic lateral sclerosis (ALS). 2024-03-27 Summary of outcomes: The TUDCA-ALS study did not meet the primary endpoint, measured by ALSFRS-R scores (a measure of functional and motor changes in ALS). There were also no significant differences observed […]
Source: www.tudca.euCategories: General Medicine News, Rare DiseaseTweet
This time the plot did not thicken... https://t.co/cIuqqfBLov https://t.co/uNpAdvlw9P